Immunotherapy

Immunotherapy drugs work by boosting the immune system so that a person’s own immune system works smarter to identify and destroy any cancer cells.
The medical management landscape for non–small cell lung cancer (NSCLC) has been changing with the rapidity of the seasons. Long gone is the day when all are treated equally.
As single-agent immunotherapies continue to show promising results, the challenge is now to determine which combination regimens with immunotherapies can improve outcomes.
As immune checkpoint inhibitors gain traction for the treatment of a variety of cancers, it is important to be aware of all the potential side effects that can occur.
In the longest follow-up on single-agent nivolumab to date, 5-year overall survival (OS) was 16% in patients with advanced non–small cell lung cancer (NSCLC) in updated results from a phase 1b dose-ranging study (CA209-003).
One of the many responsibilities of a navigator is to facilitate patient education—it is therefore imperative that we educate ourselves on new treatments, distill the information into lay terms, and use that information to effectively educate our patients.
A new study has shown that combination immunotherapy can yield significant clinical benefits—even in heavily pretreated populations.
Page 1 of 2
Results 1 - 10 of 19

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code